Should we only consider absolute risk when treating risk factors for cardiovascular disease?;Bør behandlingen av risikofaktorer for hjerte- Og karsykdom styres kun av absolutt risiko?

Tidsskrift for den Norske Laegeforening

Volumn 118, Issue 19, 1998, Pages 2966-2968

  Tonstad, Serena ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

CARDIOVASCULAR DISEASE; EUROPE; HUMAN; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; EUROPE; GUIDELINES; HUMANS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 0032551844     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Graff-Iversen S. Risiko som begrep og utfordring i helsevesenet. Tidsskr Nor Lægeforen 1996; 116: 2669-72.
2. Thelle DS. Hvordan oppfatter vi risiko? Tidsskr Nor Lægeforen 1996; 116: 3590-1.
3. Forrow L, Taylor WC, Arnold RM. Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med 1992; 92: 121-4.
4. Hetlevik I, Holmen I. Hvilket forhold har leger til risiko? Tidsskr Nor Lægeforen 1994; 114: 1709-10.
5. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ 1995; 310: 975-8.
6. Vandenbrouke JP, Westendorp RGJ. Are the effects of cholesterol lowering drugs always equal? Lancet 1996; 347: 1267-8.
7. Hetlevik I, Grimstad H. Forebygging av risiko. Tidsskr Nor Lægeforen 1997; 117: 1170-1.
8. Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Prevention of coronary heart disease in clinical practice. Eur Heart J 1994; 15: 1300-31.
9. Dyslipidaemia advisory group on behalf of the scientific committee of the National Heart Foundation of New Zealand. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. N Z Med J 1996; 109: 224-32.
10. Guidelines for the management of mildly raised blood pressure in New Zealand. Wellington: Core Services Committee, Ministry of Health, 1995.
11. Komitéen for medisinsk teknologivurdering. Behandling av mild hypertensjon. Rapport nr. 12. Oslo: Norges forskningsråd, 1997.
12. Study group, European Atherosclerosis Society. The recognition and management of hyperli pidaemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988; 9: 571-600.
13. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993; 269: 3015-23.
14. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.
15. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339-42.
16. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
17. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
18. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22.
19. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346: 1467-71.
20. Betteridge J, Shepherd J, Thompson G. Sheffield tables have shortcomings. BMJ 1997; 315: 1619.
21. Begg EJ, Nicholls MG, Richards AM. The management of mildly raised blood pressure in New Zealand: an alternative view. N Z Med J 1996; 109: 237-40.
22. Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control: what has been learned from clinical trials. I: Laragh JH, Brenner BM, red. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press, 1995: 253-70.
23. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991; 303: 893-6.
24. Tonstad S. Trenger kvinner andre stategier enn menn for å forebygge hjerte- og karsykdom? Tidsskr Nor Lægeforen 1998; 118: 739-42.
25. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
26. Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease: how well do the current cholesterol guidelines work? JAMA 1995; 274: 801-6.
27. Peyser PA. Genetic epidemiology of coronary artery disease. Epidemiol Rev 1997; 19: 80-90.
28. Superko HR. Beyond LDL cholesterol reduction. Circulation 1996; 94: 2351-4.